Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04115566

Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hidradenitis Suppurativa Bacterial Infections Bacterial Infections and Mycoses Hidradenitis Infections Skin Diseases Skin Diseases, Bacterial Skin Diseases, Infectious Skin and Connective Tissue Diseases Suppuration Sweat Gland Diseases

Age range

10 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of California San Francisco

San Francisco, California, 94115, United States

Location status: Recruiting

Location contact

Haley B Naik, MD, MHSc, FAAD

PRINCIPAL_INVESTIGATOR

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female ≥ 10 years of age
  • Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS
  • Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion criteria

  • Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.

Treatment and study plan

Primary outcomes

  1. Primary Objective

    Time frame: 2019-2035

    The primary aim of this study is to identify clinical and biologic characteristics of hidradenitis suppurativa.

Secondary outcomes

  1. Secondary Objective

    Time frame: 2019-2035

    Secondary aims include correlating alterations in clinical and biological characteristics with disease status, and identifying genetic variants that predict disease progression or response to therapy.

Study contacts

Contact information is provided by the study sponsor or research team.

Kaelin Chatterley

CONTACT

[email protected]

415-961-3786

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • UCB Pharma

Registry information

Acronym: HS PROGRESS

Important dates

Study start
2020
Primary completion
2035
Study completion
2035
First posted
Oct 4, 2019
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.